Donepezil hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for donepezil hydrochloride and what is the scope of patent protection?
Donepezil hydrochloride
is the generic ingredient in six branded drugs marketed by Eisai Inc, Corium, Chartwell Rx, Hisun Pharm Hangzhou, Macleods Pharms Ltd, Sandoz, Sun Pharm Industries, Unichem, Zydus Pharms Usa Inc, Accord Hlthcare, ACI, Actavis Elizabeth, Alembic Pharms Ltd, Apotex, Aurobindo, Cadila Pharms Ltd, Cipla Ltd, Dexcel, Dr Reddys, Dr Reddys Labs Ltd, Endo Operations, Heritage Pharma, Hetero Labs Ltd V, Hikma Pharms, Indicus Pharma, Jubilant Generics, Lupin Ltd, Natco Pharma, Osmotica Pharm Us, Prinston Inc, Rising, Sciegen Pharms Inc, Strides Pharma, Sun Pharm, Sun Pharm Inds, Sun Pharm Inds Ltd, Torrent Pharms, Twi Pharms, Wockhardt, Zydus Lifesciences, Zydus Pharms, Amneal Pharms, Ani Pharms, and Abbvie, and is included in fifty-five NDAs. There are twenty-two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Donepezil hydrochloride has one hundred and twenty-five patent family members in sixteen countries.
There are thirty drug master file entries for donepezil hydrochloride. Thirty-eight suppliers are listed for this compound. There are four tentative approvals for this compound.
Summary for donepezil hydrochloride
International Patents: | 125 |
US Patents: | 22 |
Tradenames: | 6 |
Applicants: | 44 |
NDAs: | 55 |
Drug Master File Entries: | 30 |
Finished Product Suppliers / Packagers: | 38 |
Raw Ingredient (Bulk) Api Vendors: | 158 |
Clinical Trials: | 320 |
Patent Applications: | 6,406 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for donepezil hydrochloride |
What excipients (inactive ingredients) are in donepezil hydrochloride? | donepezil hydrochloride excipients list |
DailyMed Link: | donepezil hydrochloride at DailyMed |
Recent Clinical Trials for donepezil hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Duke University | Phase 2 |
NeuroSense Therapeutics Ltd. | Phase 2 |
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 2 |
Generic filers with tentative approvals for DONEPEZIL HYDROCHLORIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 10MG | TABLET; ORAL |
⤷ Sign Up | ⤷ Sign Up | 5MG | TABLET; ORAL |
⤷ Sign Up | ⤷ Sign Up | 10MG;21MG | CAPSULE, EXTENDED RELEASE;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for donepezil hydrochloride
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for donepezil hydrochloride
Paragraph IV (Patent) Challenges for DONEPEZIL HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ARICEPT | Tablets | donepezil hydrochloride | 23 mg | 022568 | 2013-07-09 | |
ARICEPT ODT | Orally Disintegrating Tablets | donepezil hydrochloride | 5 mg and 10 mg | 021720 | 1 | 2010-06-30 |
US Patents and Regulatory Information for donepezil hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Macleods Pharms Ltd | DONEPEZIL HYDROCHLORIDE | donepezil hydrochloride | TABLET;ORAL | 202631-001 | Jan 22, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-002 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for donepezil hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-002 | Oct 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-001 | Nov 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-001 | Nov 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-001 | Nov 25, 1996 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for donepezil hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 303255 | מערכות ושיטות למתן דרך העור לטווח ארוך (Systems and methods for long term transdermal administration) | ⤷ Sign Up |
China | 101090738 | Matrix type sustained-release preparation containing basic drug or salt thereof | ⤷ Sign Up |
China | 101090737 | Matrix type sustained-release preparation | ⤷ Sign Up |
Canada | 3032044 | SYSTEME D'ADMINISTRATION TRANSDERMIQUE DE DONEPEZIL (DONEPEZIL TRANSDERMAL DELIVERY SYSTEM) | ⤷ Sign Up |
Canada | 3032148 | ADMINISTRATION TRANSDERMIQUE ENTRAINEE PAR CONVERSION PAR LE BICARBONATE DE SODIUM IN SITU DE MEDICAMENT AMINE (SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG) | ⤷ Sign Up |
Japan | 2019523268 | 塩薬物のin situでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for donepezil hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0296560 | 2/1998 | Austria | ⤷ Sign Up | PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214 |
0296560 | SPC/GB97/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.